Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficiency of moderately hypofractionated radiotherapy in NSCLC cell model.
Lüdeking M, Stemwedel K, Ramachandran D, Grosche S, Christiansen H, Merten R, Henkenberens C, Bogdanova NV. Lüdeking M, et al. Among authors: henkenberens c. Front Oncol. 2024 Apr 24;14:1293745. doi: 10.3389/fonc.2024.1293745. eCollection 2024. Front Oncol. 2024. PMID: 38720797 Free PMC article.
European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy.
Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Koerber SA, Debus J, Peeken JC, Vogel MME, Kroeze SGC, Guckenberger M, Krafcsik M, Hruby G, Emmett L, Schmidt-Hegemann NS, Trapp C, Spohn SKB, Henkenberens C, Mayer B, Shelan M, Aebersold DM, Thamm R, Wiegel T. Scharl S, et al. Among authors: henkenberens c. Radiother Oncol. 2024 May;194:110215. doi: 10.1016/j.radonc.2024.110215. Epub 2024 Mar 7. Radiother Oncol. 2024. PMID: 38458259 Free article.
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M. Adebahr S, et al. Among authors: henkenberens c. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):558-567. doi: 10.1007/s00259-023-06438-3. Epub 2023 Sep 22. Eur J Nucl Med Mol Imaging. 2024. PMID: 37736808 Free PMC article.
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.
Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, Farolfi A, Koerber SA, Debus J, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SKB, Shelan M, Aebersold DM, Grosu AL, Ceci F, Henkenberens C, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Bartenstein P, Hruby G, Scharl S, Wiegel T, Emmett L, Arnoux A, Schmidt-Hegemann NS. Zamboglou C, et al. Among authors: henkenberens c. JAMA Netw Open. 2023 May 1;6(5):e2314748. doi: 10.1001/jamanetworkopen.2023.14748. JAMA Netw Open. 2023. PMID: 37219907 Free PMC article.
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, Giuseppe Morganti A, Trapp C, Koerber SA, Debus J, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Ruf J, Grosu AL, Ceci F, Fendler WP, Bartenstein P, Kroeze SGC, Guckenberger M, Krafcsik M, Klopscheck C, Fanti S, Hruby G, Emmett L, Belka C, Stief C, Schmidt-Hegemann NS, Henkenberens C, Mayer B, Miksch J, Shelan M, Aebersold DM, Thamm R, Wiegel T. Scharl S, et al. Among authors: henkenberens c. Radiother Oncol. 2023 Jul;184:109678. doi: 10.1016/j.radonc.2023.109678. Epub 2023 May 3. Radiother Oncol. 2023. PMID: 37146766 Free article.
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, Debus J, Peeken JC, Vogel ME, Vrachimis A, Spohn SKB, Shelan M, Aebersold D, Grosu AL, Ceci F, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Hruby G, Scharl S, Wiegel T, Bartenstein P, Henkenberens C, Emmett L, Schmidt-Hegemann NS, Ferentinos K, Zamboglou C. Solomonidou N, et al. Among authors: henkenberens c. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2529-2536. doi: 10.1007/s00259-023-06185-5. Epub 2023 Mar 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 36905411 Free PMC article.
Decision regret in breast cancer patients after adjuvant radiotherapy.
Köksal M, Hoppe C, Schröder AK, Scafa D, Koch D, Sarria GR, Leitzen C, Abramian A, Kaiser C, Faridi A, Henkenberens C, Schmeel LC, Giordano FA. Köksal M, et al. Among authors: henkenberens c. Breast. 2023 Apr;68:133-141. doi: 10.1016/j.breast.2023.01.014. Epub 2023 Feb 1. Breast. 2023. PMID: 36758448 Free PMC article.
The tumor core boost study: A feasibility study of radical dose escalation to the central part of large tumors with an integrated boost in the palliative treatment setting.
Wittenstein O, Krause F, Fischer M, Domschikowski J, Nitsche M, Henkenberens C, Habermehl D, Dunst J. Wittenstein O, et al. Among authors: henkenberens c. Strahlenther Onkol. 2023 Mar;199(3):258-267. doi: 10.1007/s00066-022-01976-5. Epub 2022 Jul 20. Strahlenther Onkol. 2023. PMID: 35857073 Free PMC article. Clinical Trial.
72 results